Cysteine elevation in levodopa‐treated patients with Parkinson's disease
Identifieur interne : 002370 ( Main/Exploration ); précédent : 002369; suivant : 002371Cysteine elevation in levodopa‐treated patients with Parkinson's disease
Auteurs : Thomas Müller [Allemagne] ; Wilfried Kuhn [Allemagne]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-04-30.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Adult, Aged, Analysis of Variance, Antiparkinson Agents (therapeutic use), Cohort Studies, Cysteine, Cysteine (blood), Female, Glycine (blood), Homocystein, Human, Humans, Levodopa, Levodopa (therapeutic use), Linear Models, Male, Middle Aged, Nervous system diseases, Parkinson Disease (blood), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Severity of Illness Index, Treatment, cysteine, homocysteine, levodopa.
- MESH :
- chemical , blood : Cysteine, Glycine.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- blood : Parkinson Disease.
- drug therapy : Parkinson Disease.
- Adult, Aged, Analysis of Variance, Cohort Studies, Female, Humans, Linear Models, Male, Middle Aged, Severity of Illness Index.
Abstract
Homocysteine, cysteine, and cysteinyl‐glycine are all metabolically interrelated. Levodopa/decarboxylase inhibitor (LD/DCI) administration increases total homocysteine (tHcy) plasma levels. Objectives were to investigate associations between LD/DCI intake, concentrations of tHcy, cysteine, and cysteinyl‐glycine in PD patients and healthy controls. Cysteine levels were significant lower in controls and PD patients with tHcy below the treshold of 15 [μmol/L] when compared with PD patients with tHcy above 15. Cysteinyl‐glycine did not significantly differ between the three cohorts. Significant associations appeared between tHcys and cysteine in PD patients. tHcy and cysteine concentrations correlated to LD/DCI intake and severity of PD. The cysteine increase may be due to the significant higher dosing of daily LD/DCI and the significant higher morning LD/DCI dose 1 hour before blood sampling in PD patients with tHcy above 15 when compared with the remaining PD patients and the controls. The correlation outcomes support the view that LD/DCI intake may also increase cysteine. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22482
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000C65
- to stream Istex, to step Curation: 000C65
- to stream Istex, to step Checkpoint: 000F72
- to stream PubMed, to step Corpus: 001D95
- to stream PubMed, to step Curation: 001D95
- to stream PubMed, to step Checkpoint: 001E73
- to stream Ncbi, to step Merge: 002582
- to stream Ncbi, to step Curation: 002582
- to stream Ncbi, to step Checkpoint: 002582
- to stream Main, to step Merge: 002C31
- to stream PascalFrancis, to step Corpus: 000E87
- to stream PascalFrancis, to step Curation: 001E32
- to stream PascalFrancis, to step Checkpoint: 000F26
- to stream Main, to step Merge: 003023
- to stream Main, to step Curation: 002370
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cysteine elevation in levodopa‐treated patients with Parkinson's disease</title><author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name></author><author><name sortKey="Kuhn, Wilfried" sort="Kuhn, Wilfried" uniqKey="Kuhn W" first="Wilfried" last="Kuhn">Wilfried Kuhn</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:77920EA0F633467AC865D3D13A78773248A29A59</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22482</idno><idno type="url">https://api.istex.fr/document/77920EA0F633467AC865D3D13A78773248A29A59/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000C65</idno><idno type="wicri:Area/Istex/Curation">000C65</idno><idno type="wicri:Area/Istex/Checkpoint">000F72</idno><idno type="wicri:doubleKey">0885-3185:2009:Muller T:cysteine:elevation:in</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:19243072</idno><idno type="wicri:Area/PubMed/Corpus">001D95</idno><idno type="wicri:Area/PubMed/Curation">001D95</idno><idno type="wicri:Area/PubMed/Checkpoint">001E73</idno><idno type="wicri:Area/Ncbi/Merge">002582</idno><idno type="wicri:Area/Ncbi/Curation">002582</idno><idno type="wicri:Area/Ncbi/Checkpoint">002582</idno><idno type="wicri:Area/Main/Merge">002C31</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:09-0223229</idno><idno type="wicri:Area/PascalFrancis/Corpus">000E87</idno><idno type="wicri:Area/PascalFrancis/Curation">001E32</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000F26</idno><idno type="wicri:doubleKey">0885-3185:2009:Muller T:cysteine:elevation:in</idno><idno type="wicri:Area/Main/Merge">003023</idno><idno type="wicri:Area/Main/Curation">002370</idno><idno type="wicri:Area/Main/Exploration">002370</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Cysteine elevation in levodopa‐treated patients with Parkinson's disease</title><author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, St. Joseph Hospital Berlin‐Weißensee, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum</wicri:regionArea><wicri:noRegion>Bochum</wicri:noRegion><wicri:noRegion>Bochum</wicri:noRegion></affiliation></author><author><name sortKey="Kuhn, Wilfried" sort="Kuhn, Wilfried" uniqKey="Kuhn W" first="Wilfried" last="Kuhn">Wilfried Kuhn</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum</wicri:regionArea><wicri:noRegion>Bochum</wicri:noRegion><wicri:noRegion>Bochum</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Leopoldina Hospital, Gustav, Schweinfurt</wicri:regionArea><wicri:noRegion>Schweinfurt</wicri:noRegion><wicri:noRegion>Schweinfurt</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-04-30">2009-04-30</date><biblScope unit="vol">24</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="929">929</biblScope><biblScope unit="page" to="932">932</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">77920EA0F633467AC865D3D13A78773248A29A59</idno><idno type="DOI">10.1002/mds.22482</idno><idno type="ArticleID">MDS22482</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Analysis of Variance</term><term>Antiparkinson Agents (therapeutic use)</term><term>Cohort Studies</term><term>Cysteine</term><term>Cysteine (blood)</term><term>Female</term><term>Glycine (blood)</term><term>Homocystein</term><term>Human</term><term>Humans</term><term>Levodopa</term><term>Levodopa (therapeutic use)</term><term>Linear Models</term><term>Male</term><term>Middle Aged</term><term>Nervous system diseases</term><term>Parkinson Disease (blood)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Severity of Illness Index</term><term>Treatment</term><term>cysteine</term><term>homocysteine</term><term>levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Cysteine</term><term>Glycine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Analysis of Variance</term><term>Cohort Studies</term><term>Female</term><term>Humans</term><term>Linear Models</term><term>Male</term><term>Middle Aged</term><term>Severity of Illness Index</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Cystéine</term><term>Homme</term><term>Homocystéine</term><term>Lévodopa</term><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Traitement</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Homocysteine, cysteine, and cysteinyl‐glycine are all metabolically interrelated. Levodopa/decarboxylase inhibitor (LD/DCI) administration increases total homocysteine (tHcy) plasma levels. Objectives were to investigate associations between LD/DCI intake, concentrations of tHcy, cysteine, and cysteinyl‐glycine in PD patients and healthy controls. Cysteine levels were significant lower in controls and PD patients with tHcy below the treshold of 15 [μmol/L] when compared with PD patients with tHcy above 15. Cysteinyl‐glycine did not significantly differ between the three cohorts. Significant associations appeared between tHcys and cysteine in PD patients. tHcy and cysteine concentrations correlated to LD/DCI intake and severity of PD. The cysteine increase may be due to the significant higher dosing of daily LD/DCI and the significant higher morning LD/DCI dose 1 hour before blood sampling in PD patients with tHcy above 15 when compared with the remaining PD patients and the controls. The correlation outcomes support the view that LD/DCI intake may also increase cysteine. © 2009 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Allemagne</li></country><region><li>Berlin</li></region><settlement><li>Berlin</li></settlement></list><tree><country name="Allemagne"><region name="Berlin"><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name></region><name sortKey="Kuhn, Wilfried" sort="Kuhn, Wilfried" uniqKey="Kuhn W" first="Wilfried" last="Kuhn">Wilfried Kuhn</name><name sortKey="Kuhn, Wilfried" sort="Kuhn, Wilfried" uniqKey="Kuhn W" first="Wilfried" last="Kuhn">Wilfried Kuhn</name><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002370 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002370 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:77920EA0F633467AC865D3D13A78773248A29A59
|texte= Cysteine elevation in levodopa‐treated patients with Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |